Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Accumulated Expenses (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Accumulated Expenses for 13 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 49.06% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 49.06% decrease, with the full-year FY2025 number at $1.2 million, down 49.06% from a year prior.
  • Accumulated Expenses was $1.2 million for Q4 2025 at Ekso Bionics Holdings, up from $1.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.7 million in Q4 2023 to a low of $338000.0 in Q2 2023.
  • A 5-year average of $1.6 million and a median of $1.6 million in 2021 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 483.73% in 2024; the steepest drop was 78.86% in 2024.
  • Ekso Bionics Holdings' Accumulated Expenses stood at $2.3 million in 2021, then decreased by 0.91% to $2.3 million in 2022, then increased by 16.94% to $2.7 million in 2023, then decreased by 11.71% to $2.4 million in 2024, then crashed by 49.06% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Accumulated Expenses are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $487000.0 (Q2 2025).